TNXP, the Nasdaq-listed shares of Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company developing and commercializing treatments for central nervous system disorders, does not have a clean, current analyst consensus. Its most widely cited price targets were issued in mid-2025 — Noble Financial set a $70 target and Alliance Global Partners a $65 target, among a handful of estimates clustered roughly between $50 and $70. Those figures were established before the company's capital structure changed and are now effectively stale, so they were not used to build a central target.
Instead, the $22 figure used here reflects a more recent, post-structure TD Cowen initiation of coverage, a single-firm price objective that is discussed publicly rather than an "average analyst price target." Because only one current, attributable target could be verified, no arithmetic mean was calculated, and $22 should be read as one analyst's view, not a consensus forecast.
As of the most recent close, Tonix traded at roughly $5.17, near the low end of a 52-week range of approximately $5.01 to $20.58. A move to $22 therefore implies upside of about 325%, which must be characterized as a very large move. The gap reflects how far the shares have fallen from their 2025 peak as commercial execution lagged investor expectations and as repeated capital raises diluted existing holders.
The theoretical path to a higher valuation runs through the TONMYA launch. The company has reported product revenue of a few million dollars per quarter — preliminary third-quarter product sales of about $3.3 million were disclosed in an SEC filing — and the commercial opportunity in fibromyalgia is the core of any bull case. Reaching a $22 level would require the market to begin valuing the shares more on projected prescription growth and less on current, still-modest revenue.
The shares sit just above their 52-week low near $5.01, which now acts as a critical support level to monitor. A breakdown below that area would mark fresh multi-year weakness. On the upside, the stock's recent slide from roughly $9.65 in early October toward $5.17 leaves resistance overhead, and the prior 52-week high near $20.58 is the most significant level before the $22 objective. Notably, $22 sits only modestly above that prior high, underscoring that the target's distance stems from the depth of the current decline rather than an unprecedented valuation.
Analyst price targets typically reflect a roughly 12-month research horizon, though no explicit horizon for the $22 objective was verified. Investors should watch quarterly product revenue and TONMYA prescription trends, cash runway and any further financing, whether the company exercises its reverse-split authorization, updates to sell-side coverage, and regulatory or pipeline milestones. Each of these could materially shift the range of outcomes around the target.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile, thinly covered name like Tonix, these signals can help traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual chart review. Traders looking for an automated edge may want to explore the signals to complement their own research.
The question of whether TNXP can reach $22 ultimately hinges on whether a still-early fibromyalgia launch can grow fast enough to offset persistent dilution and cash burn. The $22 objective, a single recent analyst target rather than a consensus, requires a roughly 325% advance from near $5.17 — a very large move that would effectively restore the shares toward prior highs. Support exists in a real, commercialized product and growing revenue, while the principal obstacles are ongoing share issuance, an authorized reverse split, and a multi-year downtrend. Investors should focus on prescription momentum and the balance sheet, as those factors will likely determine whether the gap to $22 narrows or widens.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, TNXP has been closely correlated with ICU. These tickers have moved in lockstep 77% of the time. This A.I.-generated data suggests there is a high statistical probability that if TNXP jumps, then ICU could also see price increases.
| Ticker / NAME | Correlation To TNXP | 1D Price Change % | ||
|---|---|---|---|---|
| TNXP | 100% | +2.51% | ||
| ICU - TNXP | 77% Closely correlated | +2.49% | ||
| CADL - TNXP | 42% Loosely correlated | -2.99% | ||
| ZURA - TNXP | 40% Loosely correlated | +5.95% | ||
| ABSI - TNXP | 40% Loosely correlated | +2.94% | ||
| TSHA - TNXP | 40% Loosely correlated | +1.26% | ||
More | ||||